Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Medicare Director: ‘Bona-Fide’ Generic Marketing Likely Product-Specific For IRA

Jul 11 2023

• By Sarah Karlin-Smith

Protect Our Care: Lowering Drug Costs — Medicare's chief answered questions about the newly finalized IRA guidance 10 July • Source: Pink Sheet

Related Content

Medicare Negotiation Guidance Rebuts Accusations Of Constitutional ‘Due Process’ Violations

Jul 05 2023

The Immortal Humira? In Huge Test For US Biosimilar Policy, Brand May Still Have Edge

Jan 31 2023

Game On: Medicare Will Parry Manufacturer Efforts To Sidestep Price Negotiation, Guidance Says

Mar 29 2023

Medicare Negotiation Final Guidance: No More ‘Gag’ Rules, But Other Changes Fall Short Of Hopes

Jul 03 2023

Additional Topics

United States Reimbursement Pricing Debate Regulation Biosimilars Government Payers Generic Drugs BioPharmaceutical

More from Market Access

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.